Biotechnology industry association elects a new board
Biotechnology industry association elects a new board
BIO Deutschland e. V. holds its 20th ordinary general assembly
Berlin (28 September 2023) – Germany’s biotechnology industry association, BIO Deutschland, elected a new board for the next two years during its 20th ordinary general assembly yesterday.
The ten members of BIO Deutschland’s board represent various segments of the innovative biotechnology industry.
The following members were re-elected:
- Prof. Dr Kathrin Sabine Adlkofer, Chief Operating Officer and founder of Cellbox Solutions GmbH, Lübeck
- Dr Jürgen Eck, Managing Director of bio.IMPACT, Bensheim
- Norbert Hentschel, Chief Financial Officer of Miltenyi Biotec B.V. & Co. KG, Bergisch-Gladbach
- Dr Klaus Maleck, Chief Financial Officer of ITM SE, Munich
- Roland Sackers, Chief Financial Officer and Managing Director of QIAGEN N.V., Hilden
- Oliver Schacht, Ph.D., Chief Executive Officer of OpGen Inc., Rockville, MD, USA, and Chief Executive Officer of Curetis GmbH, Holzgerlingen
- Dr Sylvia Wojczewski, Chief Executive Officer of BioSpring GmbH, Frankfurt am Main
- Dr Holger Zimmermann, Chief Research and Development Officer of AiCuris Anti-infective Cures AG, Wuppertal
The following members were newly elected to the board:
- Jens Holstein, Chief Financial Officer of BioNTech SE, Mainz
- Dr Kirsten Tief-Küry, Managing Director of Life Technologies GmbH of Thermo Fisher Scientific, Darmstadt
Peter Heinrich, a long-standing member of BIO Deutschland’s board, including many years as its chair, decided it was time to step down from the board. He was honoured for his services to the association in a laudatory speech by Peter Stadler, a German biotechnology pioneer and colleague.
At the board meeting directly following the general assembly, the new board unanimously confirmed the appointment of Oliver Schacht as its chair and re-appointed Norbert Hentschel as treasurer.
“In the past few months, the ‘traffic light’ government has introduced many strategies and laws with fine-sounding names. These have also sent a number of positive signals to the biotech industry. However, many of the policies are too timid and the proposed changes are merely incremental. We need to act much faster,” says Oliver Schacht, who was appointed to a third term as chair of the association. “The enormous technological advances and discoveries made over the last 30 years have paved the way for using biotech processes to make production more sustainable and to develop new therapeutic options. BIO Deutschland will continue working tirelessly to speed up the biotech revolution for the benefit of society. I would like to thank our members and my colleagues on the board for the trust they have placed in me, and I look forward to the tasks that lie ahead.”
During the general assembly, BIO Deutschland’s management presented a comprehensive report on the association’s activities and briefly highlighted the main topics and achievements of the past twelve months.
444 words/2,956 characters including spaces
Download:
Photo caption: (from left to right) Prof. Dr Kathrin Sabine Adlkofer (Cellbox Solutions GmbH), Dr Jürgen Eck (bio.IMPACT), Norbert Hentschel (Miltenyi Biotec GmbH), Jens Holstein (BioNTech SE), Dr Klaus Maleck (ITM SE), Roland Sackers (QIAGEN N.V.), Oliver Schacht, Ph.D. (OpGen Inc./Curetis GmbH), Dr Kirsten Tief-Küry (Life Technologies GmbH of Thermo Fisher Scientific), Dr Sylvia Wojczewski (BioSpring GmbH), and Dr Holger Zimmermann (AiCuris Anti-infective Cures AG) © BIO Deutschland / S. Z. Kurc
Further information about the board can be found at: www.biodeutschland.org/en/board.html
As Germany’s biotechnology industry association, BIO Deutschland aims to support and promote the development of an innovative economic sector based on modern biosciences. The Berlin-based association currently has over 380 members, ranging from companies and bioregions to industry services providers. Oliver Schacht, Ph.D., is chair of BIO Deutschland’s board.
For more information, visit: www.biodeutschland.org
Supporting members of BIO Deutschland and industry partners are:
AGC Biologics, Avia, Baker Tilly, Bayer, BioSpring, Boehringer Ingelheim, Centogene, Citeline, CMS Hasche Sigle, Deutsche Bank, Ernst & Young, Evotec, KPMG, Lonza, Miltenyi Biotec, MorphoSys, Novartis, Pfizer, PricewaterhouseCoopers, QIAGEN, Rentschler Biopharma, Roche Diagnostics, Sanofi-Aventis Deutschland, SAP, Schmidt Versicherungs Treuhand, Simmons & Simmons, Springer Nature, Thermo Fisher Scientific, Vertex Pharmaceuticals, Vibalogics, and ZETA.
Contact:
BIO Deutschland e. V.
Dr Claudia Englbrecht
Schützenstraße 6a
10117 Berlin, Germany
Tel.: +49 30 2332 164-32
Email: englbrecht@biodeutschland.org
Publication free of charge – specimen copy requested.
